Jazz Pharmaceuticals prices upsized USD 1.1 billion exchangeable senior notes offering due 2032
Reuters2026/08/27 04:30- Jazz Pharmaceuticals priced an upsized private offering of USD 1.1 billion 1.875% exchangeable senior notes due 2032.
- Deal increased from the previously announced USD 1 billion; initial purchasers hold an option for up to USD 150 million more.
- Net proceeds estimated at about USD 1.08 billion, or about USD 1.23 billion if the option is exercised in full.
- Offering expected to close Aug. 31, 2026; proceeds earmarked for general corporate purposes.
- Concurrent with pricing, the company repurchased about USD 225 million of ordinary shares at USD 249.29 per share.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
WTI remains above $83.50 as Iran fires missiles following US strikes
Oil jumps more than 2% after US attack on Iran's Larak island
Itochu says no decision yet on reported Dentsu Soken tender offer
After Waller's hawkish speech, the market focuses on "rate hikes", but Morgan Stanley says balance sheet reduction is more likely.
After the Jackson Hole meeting, the market's focus has shifted to interest rate hike expectations. However, Morgan Stanley economist Carpenter pointed out that Walsh's long-standing stance on reducing the $7 trillion balance sheet should not be overlooked. It is expected that the Federal Reserve may begin a balance sheet reduction of more than $1.5 trillion next year, partially replacing rate hikes.
Crypto prices
More
